ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Johnson, Bruce E.; Kabbinavar, Fairooz; Fehrenbacher, Louis; Hainsworth, John D.; Kasubhai, Saifuddin M.; Kressel, Bruce; Lin, Chin-Yu; Marsland, Thomas; Patel, Taral; Polikoff, Jonathan; Rubin, Mark; White, Leonard A.; Yang, James Chih‐Hsin; Bowden, Chris; Miller, Vincent A.

doi:10.1200/jco.2012.47.3983

Cited by 156 publications

(106 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…W badaniu INFORM, w którym w leczeniu podtrzymującym stosowano gefitynib, nie stwierdzono znamiennych różnic w odniesieniu do czasu całkowitego przeżycia, natomiast czas do progresji był dłuższy w grupie otrzymującej gefitynib [128]. W badaniu ATLAS podtrzymujące leczenie zawierające bewacyzumab z erlotynibem związane było z dłuższym czasem do progresji w porównaniu z leczeniem zawierającym bewacyzumab i placebo [129].…”

Section: Inhibitory Egfr Oraz Inhibitory Receptorów Z Rodziny Herunclassified

Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: Uaktualnione zalecenia ekspertów

Jassem

Biernat

Bryl

et al. 2014

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Rak płuca jest w Polsce najczęstszą przyczyną zgonów nowotworowych. Około 85% wszystkich nowotworów płuca stanowi rak niedrobnokomórkowy (NDRP), w którym leki cytotoksyczne i ukierunkowane molekularnie odgrywają coraz większą rolę. W pracy przedstawiono oparte na obecnej wiedzy zalecenia dotyczące stosowania tych metod w praktyce klinicznej u chorych na NDRP oraz na złośliwego międzybłoniaka opłucnej.

show abstract

Section: Inhibitory Egfr Oraz Inhibitory Receptorów Z Rodziny Herunclassified

Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: Uaktualnione zalecenia ekspertów

Jassem

Biernat

Bryl

et al. 2014

Advances in Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…Among 743 patients included in the final analyses, 29 presented BM at baseline. A pooled analyses (33) of the 131 patients with treated BM receiving bevacizumab in either PASSPORT (28) or ATLAS (29) reported no symptomatic grade >2 brain haemorrhage during the main treatment phases of study. In the ATLAS trial one grade 2 CNS haemorrhage occurred during treatment after CNS progression (29).…”

Section: Angiogenesis In Brain Metastasesmentioning

confidence: 99%

“…Bevacizumab safety was first investigated in patients with asymptomatic treated BM. Five prospective trials, PASSPORT, ATLAS, BeTa, ERACLE and PRONOUNCE trials included patients with treated BM and recorded a low rate of CNS haemorrhage (28)(29)(30)(31)(32).…”

Section: Angiogenesis In Brain Metastasesmentioning

confidence: 99%

Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer

Buttigliero

Bertaglia

Novello

2016

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Central nervous system (CNS) metastases are common in patients with advanced non-small cell lung cancer (NSCLC), occurring in 24% to 44% of patients in the course of their disease and confer significant morbidity and mortality. Systemic therapies have been deemed ineffective in brain metastases (BM) under the hypothesis that the blood-brain barrier (BBB) limits their delivery to the brain. Angiogenesis, which is mainly mediated by vascular endothelial growth factor (VEGF) pathway, is crucial for tumor survival, growth and invasion both in primary and metastatic brain lesions. Two major categories of agents have been developed to target this pathway: antibody-based agents and VEGF receptor tyrosine kinase inhibitors (TKIs). Clinical benefits have been shown with anti-angiogenetic therapies in the treatment of metastatic NSCLC. However, patients with CNS metastases were often excluded from trials with these agents, due to concerns about a potentially greater risk of cerebral haemorrhage and thromboembolic disease. Therefore, the overall efficacy and safety of angiogenetic agents in patients with BM from NSCLC are yet to be clarified. This paper aims to review available data about the efficacy and safety of antiangiogenetic therapies for CNS metastases in NSCLC patients.

show abstract

“…The ATLAS trial randomized 743 patients to bevacizumab or bevacizumab plus erlotinib maintenance after completion of 4 cycles of chemotherapy and bevacizumab [29]. Investigators were allowed to choose from six platinum-containing induction regimens.…”

Section: Trials With An Os Benefitmentioning

confidence: 99%

Complex Decisions for First-Line and Maintenance Treatment of Advanced Wild-Type Non-Small Cell Lung Cancer

Gentzler

Johnson

2015

The Oncologist

View full text Add to dashboard Cite

Until recently, the first-line treatment of advanced non-small cell lung cancer (NSCLC) required minimal clinical decision making. Patients who were eligible for chemotherapy received a platinum-based doublet, and 5-year survival rates were poor. With the advent of molecularly targeted agents and better tolerated chemotherapies-namely, bevacizumab, erlotinib, and pemetrexed-new therapeutic opportunities have emerged. Some of the strategies that have proven to be successful for the treatment of patients with NSCLC are targeting of the vascular endothelial growth factor, use of maintenance chemotherapy for patients without progression of disease after initial therapy, and tailoring of cytotoxic agents specific to the histology of an individual patient's cancer. Each approach has been independently shown to improve overall survival, but integrating the data from a number of complicated trialsintothe"best"approach for patients remains challenging. This review attempts to address three fundamental questions clinicians face in choosing first-line and maintenance treatment for advanced NSCLC, particularly nonsquamous histology: Is pemetrexed or a taxane agent better for combination with platinum therapy? Should bevacizumab be used, and is it beneficial when added to pemetrexed chemotherapy? When is maintenance therapy indicated, and which agent is best? The Oncologist 2015;20:299-306

show abstract

ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Cited by 156 publications

References 18 publications

Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: Uaktualnione zalecenia ekspertów

Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: Uaktualnione zalecenia ekspertów

Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer

Complex Decisions for First-Line and Maintenance Treatment of Advanced Wild-Type Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About